Is Single-Dose Intraoperative IP Carboplatin Feasible in Advanced Ovarian Cancer?
Posted: Thursday, December 3, 2020
Therapies for advanced epithelial ovarian cancer such as intraperitoneal (IP) chemotherapy and hyperthermic IP chemotherapy are often associated with high morbidity, contributing to treatment delay. An alternate treatment is normothermic IP carboplatin after primary or interval debulking surgery. A phase II, nonrandomized, prospective study, conducted by Shivdas et al at the Kidwai Memorial Institute of Oncology, India, assessed this patient population’s regimen. Their results were published in a poster during the 2020 International Gynecologic Cancer Society (IGCS) Annual Global Meeting (Abstract 1395).
“Single-dose normothermic intraoperative IP carboplatin is a feasible procedure with no or minimal manageable morbidity,” concluded the researchers.
The study took place from January 2015 through December 2019. A single dose of intraoperative IP therapy was given to patients with cytoreduced high-grade serous ovarian cancer. Perioperative complications were classified based on their proximity to administration and were categorized as immediate (< 6 hours), early (6–48 hours), or late (48 hours–21 days).
A total of 356 patients with advanced epithelial ovarian cancer were eligible, 86 of whom met both the inclusion and exclusion criteria. Of these patients, 12 (14%) had primary debulking surgery, and 74 (86%) had interval debulking surgery; 13 of the latter group underwent laparoscopic or robotic surgery.
According to the study authors, IP carboplatin was well tolerated by all patients; few adverse events were recorded. Paralytic ileus occurred in three patients, a burst abdomen requiring resuturing was reported in three others, and a single patient underwent re-exploratory surgery for hemorrhage. One patient developed sepsis and died.
“Our study is hypothesis generating for future clinical trials comparing single dose normothermic IP carboplatin versus hyperthermic IP chemotherapy in advanced epithelial ovarian cancer,” the investigators commented.
Disclosure: No disclosure information for the study authors was provided.